157 related articles for article (PubMed ID: 38116408)
1. Novel Pyrido[3,2-
Sabnis RW
ACS Med Chem Lett; 2023 Dec; 14(12):1627-1628. PubMed ID: 38116408
[TBL] [Abstract][Full Text] [Related]
2. Novel Tetrahydropyrido[3,4-
Sabnis RW
ACS Med Chem Lett; 2024 Mar; 15(3):318-319. PubMed ID: 38505843
[TBL] [Abstract][Full Text] [Related]
3. Novel Diaminopyrimidine Carboxamides as HPK1 Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2023 Jul; 14(7):899-900. PubMed ID: 37465291
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Zhang J; Li Y; Tang H; Zhou Q; Tong L; Ding J; Xie H; Xiong B; Liu T
Bioorg Chem; 2023 Nov; 140():106811. PubMed ID: 37659145
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Wu F; Li H; An Q; Sun Y; Yu J; Cao W; Sun P; Diao X; Meng L; Xu S
Eur J Med Chem; 2023 Jun; 254():115355. PubMed ID: 37062169
[TBL] [Abstract][Full Text] [Related]
6. Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 Feb; 15(2):177-178. PubMed ID: 38352847
[TBL] [Abstract][Full Text] [Related]
7. Novel Tyrosine Kinase 2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 Jun; 15(6):769-770. PubMed ID: 38894908
[TBL] [Abstract][Full Text] [Related]
8. TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 Mar; 15(3):320-321. PubMed ID: 38505839
[TBL] [Abstract][Full Text] [Related]
9. Pyrrolidinone Derivatives as NIK Inhibitors for Treating Inflammatory and Autoimmune Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 Mar; 15(3):322-323. PubMed ID: 38505855
[TBL] [Abstract][Full Text] [Related]
10. Pyrrolidinone Derivatives as NIK Inhibitors for Treating Autoimmune and Inflammatory Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 May; 15(5):581-582. PubMed ID: 38746901
[TBL] [Abstract][Full Text] [Related]
11. Novel IRAK4 Inhibitors for Treating Asthma, COPD, Cancer, Autoinflammatory Diseases, and Autoimmune Diseases.
Sabnis RW
ACS Med Chem Lett; 2023 Dec; 14(12):1617-1618. PubMed ID: 38116447
[TBL] [Abstract][Full Text] [Related]
12. Boron-Containing Pyrazole Compounds as JAK Inhibitors for Treating Inflammation, Autoimmune Diseases, and Cancer.
Sabnis RW
ACS Med Chem Lett; 2022 Oct; 13(10):1554-1555. PubMed ID: 36267133
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
Rewcastle GW; Palmer BD; Thompson AM; Bridges AJ; Cody DR; Zhou H; Fry DW; McMichael A; Denny WA
J Med Chem; 1996 Apr; 39(9):1823-35. PubMed ID: 8627606
[TBL] [Abstract][Full Text] [Related]
14. Novel Thienopyrrole Compounds for Treating Autoimmune Diseases and Inflammatory Conditions.
Sabnis RW
ACS Med Chem Lett; 2023 May; 14(5):549-550. PubMed ID: 37197455
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of analgesic, anti-inflammatory and ulcerogenic activities of some triazolo- and 2-pyrazolyl-pyrido[2,3-d]-pyrimidines.
Hafez HN; Abbas HA; El-Gazzar AR
Acta Pharm; 2008 Dec; 58(4):359-78. PubMed ID: 19103572
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antiallergy activity of 10-oxo-10H-pyrido[1,2-a]thieno[3,2-d]pyrimidines and 10-oxo-10H-pyrido[1,2-a]thieno[3,4-d]pyrimidines.
Connor DT; Sorenson RJ; Cetenko WA; Kerbleski JJ; Tinney FJ
J Med Chem; 1984 Apr; 27(4):528-30. PubMed ID: 6142956
[TBL] [Abstract][Full Text] [Related]
17. Advances in the Chemistry of 6-6 Bicyclic Systems: Chemistry of Pyrido[3,4- d]pyrimidines.
Monier M; Abdel-Latif D; El-Mekabaty A; Mert BD; Elattar KM
Curr Org Synth; 2019; 16(6):812-854. PubMed ID: 31984909
[TBL] [Abstract][Full Text] [Related]
18. An overview on synthetic and pharmaceutical prospective of pyrido[2,3-d]pyrimidines scaffold.
Yadav P; Shah K
Chem Biol Drug Des; 2021 Mar; 97(3):633-648. PubMed ID: 32946161
[TBL] [Abstract][Full Text] [Related]
19. Exploration of Pyrido[3,4-
Van Hoof M; Claes S; Boon K; Van Loy T; Schols D; Dehaen W; De Jonghe S
Molecules; 2023 Feb; 28(5):. PubMed ID: 36903345
[TBL] [Abstract][Full Text] [Related]
20. Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors.
Wissing J; Godl K; Brehmer D; Blencke S; Weber M; Habenberger P; Stein-Gerlach M; Missio A; Cotten M; Müller S; Daub H
Mol Cell Proteomics; 2004 Dec; 3(12):1181-93. PubMed ID: 15475568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
